THER-01. PRECLINICAL DEVELOPMENT OF EO1001, A NOVEL IRREVERSIBLE BRAIN PENETRATING PAN-ErbB INHIBITOR

Dysregulation of ErbB-mediated signaling is observed in up to 90% of solid tumors. ErbB family cross-talk is implicated in the development of resistance and metastasis, including CNS metastases. Inhibition of multiple ErbB receptors may result in improved patient outcomes. EO1001 is a novel, patente...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Wang, Bacha, Jeffrey, Brown, Dennis, Kanekal, Sarath, Sankar, Neil, Wang, ZhenZhong, Pedersen, Harry, Butowski, Nicholas, Nicolaides, Theodore, Sarkaria, Jann, James, C David, Giles, Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213116/
http://dx.doi.org/10.1093/noajnl/vdz014.044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213116/
http://dx.doi.org/10.1093/noajnl/vdz014.044

Ejemplares similares